Table 2.

Characteristics of WHISCA CEE sample at WHI baseline by treatment assignment, including age and 3MS score at WHISCA initial assessment and time from randomization

Variable	CEE	Placebo	Test of homogeneity
Age at WHISCA initial assessment, mean (sd), yr	74.01 (3.73)	74.02 (3.92)	0.988
Time from WHI randomization to WHISCA initial assessment, mean (sd), yr	3.02 (0.70)	3.01 (0.67)	0.841
3MS total score at WHI enrollment	95.13 (3.88)	95.49 (4.00)	0.506
3MS total score at WHISCA enrollment	95.35 (3.89)	95.49 (4.00)	0.596
Education, n (%)			0.809
Less than high school	26 (6.00)	27 (5.99)
High school/GED	115 (26.56)	107 (23.73)
>High school, less than 4 yr college	176 (40.65)	191 (42.35)
4 yr or more of college	116 (26.79)	126 (27.94)
Race/ethnicity (%)			0.662
White, non-Hispanic	372 (85.91)	392 (86.92)
Nonwhite/other	61 (14.09)	59 (13.08)
Body mass index, kg/m2, mean (sd)	29.40 (6.23)	29.21 (5.60)	0.644
Smoking status, n (%)			0.031
Never	257 (59.77)	244 (54.46)
Former	157 (36.51)	170 (37.95)
Current	16 (3.72)	34 (7.59)
Alcoholic drinks per week, n (%)			0.098
0	211 (48.62)	225 (50.00)
1–6	189 (43.55)	173 (38.44)
7+	34 (7.83)	52 (11.56)
Prior CVD, n (%)			0.722
No	384 (88.48)	395 (87.39)
History of stroke	5 (1.15)	8 (1.77)
History of other CVD	45 (10.37)	49 (10.84)
Hypertension at WHI baseline, n (%), no/yes	201 (46.31)/233 (53.69)	221 (48.89)/231 (51.11)	0.442
Diabetes, n (%), no/yes	390 (89.86)/44 (10.14)	403 (89.16)/49 (10.84)	0.733
Moderate/severe vasomotor symptoms, n (%), no/yes	391 (90.72)/40 (9.28)	407 (90.44)/43 (9.56)	0.889
Prior hormone therapy, n (%)
Any prior use	215 (49.54)	209 (46.24)	0.326
Among those with prior use: duration less than 10 yr	134 (62.33)	140 (66.99)	0.316

CVD, Cardiovascular disease.